Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Liver Disease

HomeCirculationVol. 147, No. 10Use of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Liver Disease No AccessEditorialRequest AccessFull TextAboutView Full TextView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toNo AccessEditorialRequest AccessFull TextUse of Direct-Acting Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Liver Disease Theresa J. Hydes, PhD, Gregory Y.H. Lip, MD and Deirdre A. Lane, PhD Theresa J. HydesTheresa J. Hydes Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, UK (T.J.H., G.Y.H.L., D.A.L.). Liverpool University Hospitals National Health Service Foundation Trust, Aintree University Hospital, Lower Lane, UK (T.J.H.). , Gregory Y.H. LipGregory Y.H. Lip https://orcid.org/0000-0002-7566-1626 Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, UK (T.J.H., G.Y.H.L., D.A.L.). Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart 147:795–797This article is a commentary on the followingComparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort StudyFootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.For Disclosures, see page 797.Circulation is available at www.ahajournals.org/journal/circCorrespondence to: Deirdre A. Lane, PhD, Liverpool Centre for Cardiovascular Sciences, University of Liverpool, 6 West Derby Street, Liverpool, UK L7 8TX. Email email protectednetReferences1. O'Shea RS, Davitkov P, Ko CW, Rajasekhar A, Su GL, Sultan S, Allen AM, Falck-Ytter Y. AGA clinical practice guideline on the management of coagulation disorders in patients with cirrhosis.Gastroenterology. 2021; 161:1615–1627.e1. doi: 10.1053/j.gastro.2021.08.015CrossrefMedlineGoogle Scholar2. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, et al. Edoxaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2013; 369:2093–2104. doi: 10.1056/NEJMoa1310907CrossrefMedlineGoogle Scholar3. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365:883–891. doi: 10.1056/NEJMoa1009638CrossrefMedlineGoogle Scholar4. Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al. Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365:981–992. doi: 10.1056/NEJMoa1107039CrossrefMedlineGoogle Scholar5. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al. Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009; 361:1139–1151. doi: 10.1056/NEJMoa0905561CrossrefMedlineGoogle Scholar6. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.J Am Coll Cardiol. 2019; 74:104–132. doi: 10.1016/j.jacc.2019.01.011CrossrefMedlineGoogle Scholar7. Fu Y, Zhu W, Zhou Y, Chen H, Yan L, He W. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review.Am J Cardiovasc Drugs. 2020; 20:139–147. doi: 10.1007/s40256-019-00369-xCrossrefMedlineGoogle Scholar8. Jamwal R, de La Monte SM, Ogasawara K, Adusumalli S, Barlock BB, Akhlaghi F. Nonalcoholic fatty liver disease and diabetes is associated with decreased CYP3A4 protein expression and activity in human liver.Mol Pharm. 2018; 15:2621–2632. doi: 10.1021/acs.molpharmaceut.8b00159CrossrefMedlineGoogle Scholar9. Steensig K, Pareek M, Krarup AL, Sogaard P, Maeng M, Tayal B, Lee CJY, Torp-Pedersen C, Lip GY, Holland-Fischer P, et al. Thromboembolism and bleeding in patients with atrial fibrillation and liver disease: a nationwide register-based cohort study: thromboembolism and bleeding in liver disease.Clin Res Hepatol Gastroenterol. 2022; 46:101952. doi: 10.1016/j.clinre.2022.101952CrossrefMedlineGoogle Scholar10. Proietti M, Marzona I, Vannini T, Colacioppo P, Tettamanti M, Foresta A, Fortino I, Merlino L, Lip GYH, Roncaglioni MC. Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study.Eur Heart J Cardiovasc Pharmacother. 2021; 7:F84–F92. doi: 10.1093/ehjcvp/pvaa015CrossrefMedlineGoogle Scholar11. Pastori D, Lip GYH, Farcomeni A, del Sole F, Sciacqua A, Perticone F, Marcucci R, Grifoni E, Pignatelli P, Violi F, et al. Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants.Int J Cardiol. 2018; 264:58–63. doi: 10.1016/j.ijcard.2018.01.097CrossrefMedlineGoogle Scholar12. Lawal OD, Aronow HD, Shobayo F, Hume AL, Taveira TH, Matson KL, Zhang Y, Wen X. Comparative effectiveness and safety of direct oral anticoagulants and warfarin in patients with atrial fibrillation and chronic liver disease: a nationwide cohort study.Circulation. 2023; 147:782–794. doi: 10.1161/CIRCULATIONAHA.122.060687LinkGoogle Scholar13. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Eur Heart J. 2018; 39:1330–1393. doi: 10.1093/eurheartj/ehy136CrossrefMedlineGoogle Scholar14. Villa E, Bianchini M, Blasi A, Denys A, Giannini EG, de Gottardi A, Lisman T, de Raucourt E, Ripoll C, Rautou PE. EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis.J Hepatol. 2022; 76:1151–1184. doi: 10.1016/j.jhep.2021.09.003CrossrefMedlineGoogle Scholar15. Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, Mueck W. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct factor Xa inhibitor.Br J Clin Pharmacol. 2013; 76:89–98. doi: 10.1111/bcp.12054CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsRelated articlesComparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort StudyOluwadolapo D. Lawal, et al. Circulation. 2023;147:782-794 March 7, 2023Vol 147, Issue 10 Advertisement Article InformationMetrics © 2023 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.122.063195PMID: 36877772 Originally publishedMarch 6, 2023 Keywordsdirect-acting oral anticoagulantsEditorialsatrial fibrillationchronic liver diseasePDF download Advertisement SubjectsArrhythmiasAtrial FibrillationCardiovascular Disease